Global healthcare company Sanofi and therapeutic companion software company Voluntis have agreed to a collaboration to help improve decision-making and self-management for type 2 diabetics treated with basal insulin. The
Tag "Insulin"
The European Commission (EC) has granted marketing authorisation in Europe for Sanofi‘s Suliqua, a titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the
Advertisements
